Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C plus regional hyperthermia feasibility study in non-muscle invasive bladder cancer
NL-OMON32637Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS), sponsored by Amsterdam University Medical Center. Primary endpoints: Toxicity and Treatment discontinuation due to toxicity. Planned start Sep 2008; status: not yet recruiting.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON32637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32637.